Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,235 shares of the medical equipment provider’s stock after purchasing an additional 4,569 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Zimmer Biomet were worth $3,067,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. OLD Point Trust & Financial Services N A purchased a new stake in Zimmer Biomet in the 4th quarter valued at about $26,000. Ables Iannone Moore & Associates Inc. purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $30,000. Naples Money Management LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $35,000. J.Safra Asset Management Corp boosted its stake in shares of Zimmer Biomet by 712.1% in the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 235 shares during the period. Finally, Activest Wealth Management lifted its stake in Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 275 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZBH has been the subject of a number of recent research reports. Argus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Tuesday, May 21st. Morgan Stanley decreased their price target on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Barclays cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Evercore ISI cut their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating on the stock in a report on Tuesday, July 2nd. Finally, Citigroup cut their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $129.53.

Zimmer Biomet Stock Performance

ZBH traded up $0.55 during trading on Wednesday, hitting $110.55. The stock had a trading volume of 923,810 shares, compared to its average volume of 1,494,045. The firm has a market capitalization of $22.74 billion, a P/E ratio of 23.81, a PEG ratio of 1.99 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $142.54. The company’s 50-day moving average price is $111.04 and its 200 day moving average price is $119.75. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.89 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.